检索结果 - Peter Vandenberghe

Refine Results
  1. 1
    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia

    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia 由 Els Lierman, Dominik Selleslag, Sanne Smits, Johan Billiet, Peter Vandenberghe

    出版 2012
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  2. 2
    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) 由 Bartosz Wasąg, Els Lierman, Mira Meeus, Jan Cools, Peter Vandenberghe

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model

    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model 由 Stefaan W. Van Gool, Peter Vandenberghe, Mark de Boer, Jan Ceuppens

    出版 1996
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases 由 Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    出版 2012
    获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines

    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines 由 Jan Delabie, Jan Ceuppens, Peter Vandenberghe, Mark de Boer, Lieve Coorevits, Chris Peeters

    出版 1993
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation

    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation 由 Katherine Vandenborre, Stefaan W. Van Gool, Ahmad Kasran, Jan Ceuppens, M. Boogaerts, Peter Vandenberghe

    出版 1999
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances

    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances 由 Sabine Franke, Iwona Włodarska, Brigitte Maes, Peter Vandenberghe, Jan Delabie, Anne Hagemeijer, Chris De Wolf‐Peeters

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern 由 José Luis Ferreiro, Julie Morscio, Daan Dierickx, Lukas Marcelis, G. Verhoef, Peter Vandenberghe, Thomas Tousseyn, Iwona Wlodarska

    出版 2015
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  9. 9
    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data 由 Gils Roex, Tom Feys, Yves Béguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  10. 10
    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for I... 由 Johan Maertens, Jan Verhaegen, Hilde Demuynck, Penelope Brock, Gregor Verhoef, Peter Vandenberghe, Johan Van Eldere, L. Verbist, Marc Boogaerts

    出版 1999
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features

    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features 由 José Luis Ferreiro, Julie Morscio, Daan Dierickx, Peter Vandenberghe, Olivier Gheysens, G. Verhoef, M. Zamani, Thomas Tousseyn, Iwona Włodarska

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others... 由 Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, José Thomas, Peter Vandenberghe, Jan Balzarini, Christine De Wolf‐Peeters, Luc Mortelmans, Gregor Verhoef

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation 由 Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes

    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes 由 Michel Delforge, H Demuynck, Peter Vandenberghe, G. Verhoef, Pierre Zachée, V. Van Duppen, P Marijnen, Herman Van den Berghe, MA Boogaerts

    出版 1995
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant 由 Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis

    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis 由 Zhanju Liu, Karel Geboes, Peter W. Hellings, Philippe Maerten, Hubertine Heremans, Peter Vandenberghe, Louis Boon, Peter van Kooten, Paul Rutgeerts, Jan Ceuppens

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma 由 Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, José Thomas, Tjibbe de Groot, Jan Balzarini, C. De Wolf‐Peeters, L. Mortelmans, G. Verhoef

    出版 2002
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas

    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas 由 Iwona Włodarska, Daan Dierickx, Vera Vanhentenrijk, Katrien Van Roosbroeck, H Pospíšilová, Francesca Minnei, Gregor Verhoef, José Thomas, Peter Vandenberghe, Chris De Wolf‐Peeters

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia 由 Kim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, Cedric Folens, Leander Van Neste, Sofie Bekaert, Peter Vandenberghe, María D. Odero, Peter Marynen, Jan Cools

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions 由 Katrien Van Roosbroeck, Jan Cools, Daan Dierickx, José Thomas, Peter Vandenberghe, Michel Stul, Jan Delabie, Chris De Wolf‐Peeters, Peter Marynen, Iwona Włodarska

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: